Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 9/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306370 | 0.81 | NR1H2 (0.43) | ACLYLMNA | |
| SCHEMBL2207149 | 0.79 | IDO1 (0.56) | HPGDKDM4EMAPTALDH1A1GAA | |
| SCHEMBL17859653 | 0.79 | HPGD (0.49) | HPGDKDM4EMAPTALDH1A1GAA | |
| SCHEMBL6774397 | 0.79 | KDM4E (0.39) | HPGDKDM4EMAPTACLYGAA | |
| SCHEMBL8688214 | 0.78 | APLNR (0.53) | HPGDMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL6831445 | 0.78 | HPGD (0.43) | HPGDKDM4EMAPTALDH1A1ACLY | |
| SCHEMBL15414917 | 0.77 | TRPV4 (0.54) | L3MBTL1 | |
| SCHEMBL27736542 | 0.77 | KDM4E (0.44) | HPGDKDM4EMAPTALDH1A1GAA | |
| SCHEMBL15414218 | 0.77 | PYCR1 (0.44) | KDM4EMAPTALDH1A1GAALMNA | |
| Alcohol SCHEMBL7237276 | 0.75 | IDO1 (0.51) | HPGDKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | HPGD 2381/4885KDM4E 760/4885MAPT 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.